


FARMACOCINÉTICA DEL ÁCIDO TRANEXÁMICO ADMINISTRADO TÓPICAMENTE EN CIRUGÍA DE ARTROPLASTIA TOTAL DE RODILLA PRIMARIA

JOAN I. SUGRAÑES CAMPRUBÍ, ARANZAZU GONZÁLEZ, XAVIER AGUILERA,
JOSE CARLOS GONZÁLEZ, MARCOS JORDÁN, SEBASTIÀ VIDELA

OBJETIVOS



MATERIAL Y METODOLOGÍA

INTRAVENOSO

2 DOSIS (1.000mg)

- 15-30min previo
isquemia

- 90-140min desde 1^a dosis

TÓPICO

ÚNICA DOSIS (1.000mg)

- Previo cierre HQ

24

MATERIAL Y METODOLOGÍA

INTRAVENOSO

8 MUESTRAS (3mL)

- 1 pre y 30min tras 1ª D
- 1 pre y 6 dosis tras 2ª D


TÓPICO

10 MUESTRAS (3mL)

- 1 pre y 9 tras D



RESULTADOS



TÓPICO

INTRAVENOSO

RESULTADOS

Parameter	Population mean (%RSE)	%IV (%RSE)	Population mean bootstrap (CI 95%)	%IV Bootstrap
CI (L/h) = $\theta_1 + \theta_{10}$				
θ_1		12,53 (30,64)	5,33 (4,88 – 5,79)	11,50 (7,26 – 14,90)
θ_{10}			0,0426 (0,0426 – 0,0426)	
V_c (L)		12,12 (71,42)		
Q (L/h)				
V_p (L)				
k_a (1/h)	0,780 (12,36)	32,09 (49,90)	0,77 (0,77 – 0,77)	32,09 (49,90)
Lag Time (h)	0,450 (4,95)	17,00 (75,93)	0,448 (0,410 – 0,486)	17,00 (75,93)
F	0,814 (4,94)		0,819 (0,739 – 0,897)	
Covariance between CI and V_c	0,5			
Residual error (%)			0,04 (6,50% -9,78%)	


CI=Clearance; V_c = Central volume of distribution; k_a = First-order absorption constant; RSE= Relative standard error of estimation (estimation error divided by parameter value); CI= Confidence interval 95%.

BIODISPONIBILIDAD
81.9%

VALOR >5mg/L
100%

SIN TOXICIDAD
<150mg/L

DISCUSIÓN



TÓPICO

INTRAVENOSO

CONCLUSIONES

ATX TÓPICO

- ↑ Biodisponibilidad
- Absorción lenta
 - ↓ CMax
- ↓ RRAA
 - TVP, Convulsiones, ERC...

1g ATX
(Tópico)

>5mg/L

>8h

<150mg/L

BIBLIOGRAFÍA

- ▶ Roberto Picetti, Haleema Shakur-Still, Robert L Medcalf, Joseph F Standing, Ian Roberts. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. *Blood Coagul Fibrinolysis*. 2019 Jan;30(1):1-10.
- ▶ Aguilera X, Martínez-Zapata MJ, Hinarejos P, Jordán M, Leal J, González J. C, Monllau J. C, Celaya F, Rodríguez-Arias A, Fernández J. A, Pelfort X, Puig-Verdie L.I. Topical and intravenous tranexamic acid reduce blood loss compared to routine hemostasis in total knee arthroplasty: a multicenter, randomized, controlled trial”. *Arch Orthop Trauma Surg*. 2015; 135:1017-25.
- ▶ CRASH-2 trial collaborators, Shakur H, Roberts I, et al. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. *Lancet*. 2010;376(9734):23-32.
- ▶ Effectiveness of tranexamic acid in revision total knee arthroplasty”. Aguilera X, Videla S, Almenara M, Fernández JA, Gich I, Celaya F *Acta Orthop Belg*. 2012; 78:68-74.
- ▶ Picetti R, Shakur-Still H, Medcalf RL, Standing JF, Roberts I. What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. *Blood Coagul Fibrinolysis*. 2019;30(1):1-10.
- ▶ Lecker I, Wang DS, Whissell PD, Avramescu S, Mazer CD, Orser BA. Tranexamic acid-associated seizures: Causes and treatment. *Ann Neurol*. 2016;79(1):18-26.
- ▶ Xu S, Chen JY, Zheng Q, et al. The safest and most efficacious route of tranexamic acid administration in total joint arthroplasty: A systematic review and network meta-analysis. *Thromb Res*. 2019;176:61-66.

MUCHAS GRACIAS

9 CONGRESO CONJUNTO
AEA - SEROD
9th JOINT AEA-SEROD CONGRESS

